A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.

A phase 1 study of 131I-CLR1404 in patients with relapsed or refractory advanced solid tumors: dosimetry, biodistribution, pharmacokinetics, and safety.

(131)I-CLR1404 is a small molecule that combines a tumor-targeting moiety with a therapeutic radioisotope. The primary aim of this phase 1 study was to determine the administered radioactivity expected to deliver 400 mSv to the bone marrow. The secondary aims were to determine the pharmacokinetic (P...

Full description

Bibliographic Details
Main Authors: Joseph J Grudzinski, Benjamin Titz, Kevin Kozak, William Clarke, Ernest Allen, LisaAnn Trembath, Michael Stabin, John Marshall, Steve Y Cho, Terence Z Wong, Joanne Mortimer, Jamey P Weichert
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4234270?pdf=render

Internet

http://europepmc.org/articles/PMC4234270?pdf=render

Similar Items